ArticleOncogenesis2024

TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma.

Dongbo Qiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.